1461 related articles for article (PubMed ID: 19628181)
21. 3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents.
De Felice F; Fiorilli R; Parma A; Nazzaro M; Musto C; Sbraga F; Caferri G; Violini R
JACC Cardiovasc Interv; 2009 Dec; 2(12):1260-5. PubMed ID: 20129553
[TBL] [Abstract][Full Text] [Related]
22. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.
Kukreja N; Onuma Y; Garcia-Garcia HM; Daemen J; van Domburg R; Serruys PW;
JACC Cardiovasc Interv; 2009 Jun; 2(6):534-41. PubMed ID: 19539258
[TBL] [Abstract][Full Text] [Related]
23. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
Brodie BR; Wilson H; Stuckey T; Nussbaum M; Laurent S; Bradshaw B; Humphrey A; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
[TBL] [Abstract][Full Text] [Related]
24. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
[TBL] [Abstract][Full Text] [Related]
25. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
[TBL] [Abstract][Full Text] [Related]
26. A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus nondiabetic patients.
Minha S; Bental T; Assali A; Vaknin-Assa H; Lev EI; Rechavia E; Battler A; Kornowski R
Catheter Cardiovasc Interv; 2011 Nov; 78(5):710-7. PubMed ID: 21805561
[TBL] [Abstract][Full Text] [Related]
27. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction.
Lee MS; Sillano D; Latib A; Chieffo A; Zoccai GB; Bhatia R; Sheiban I; Colombo A; Tobis J
Catheter Cardiovasc Interv; 2009 Jan; 73(1):15-21. PubMed ID: 19089930
[TBL] [Abstract][Full Text] [Related]
28. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
29. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
[TBL] [Abstract][Full Text] [Related]
30. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
[TBL] [Abstract][Full Text] [Related]
31. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
[TBL] [Abstract][Full Text] [Related]
32. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
Leon MB; Allocco DJ; Dawkins KD; Baim DS
JACC Cardiovasc Interv; 2009 Jun; 2(6):504-12. PubMed ID: 19539253
[TBL] [Abstract][Full Text] [Related]
33. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation.
Auer J; Leitner A; Berent R; Lamm G; Lassnig E; Krennmair G
Atherosclerosis; 2010 Jun; 210(2):503-9. PubMed ID: 20060973
[TBL] [Abstract][Full Text] [Related]
35. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
[TBL] [Abstract][Full Text] [Related]
36. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Naim C; Kawaguchi M; Giannini F; Colombo A
JACC Cardiovasc Interv; 2013 Nov; 6(11):1153-9. PubMed ID: 24262615
[TBL] [Abstract][Full Text] [Related]
37. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
[TBL] [Abstract][Full Text] [Related]
38. In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.
Tolerico PH; Cohen DJ; Kleiman NS; Berger PB; Brilakis ES; Piana RN; Shammo S; Keyes MJ; Kennedy KF; Massaro JM; Saucedo JF;
Catheter Cardiovasc Interv; 2012 Dec; 80(7):1127-36. PubMed ID: 22431166
[TBL] [Abstract][Full Text] [Related]
39. Comparison of drug-eluting and bare-metal stents for stable coronary artery disease.
Horst B; Rihal CS; Holmes DR; Bresnahan JF; Prasad A; Gau G; Lennon R; Lerman A
JACC Cardiovasc Interv; 2009 Apr; 2(4):321-8. PubMed ID: 19463444
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
